Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035100 · ClinicalTrials.gov registry record · Phase 2
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
A Phase 2 study of Ovarian Neoplasms and Peritoneal Neoplasms, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 8
- Study locations
NCT00035100: Completed Phase 2 study of Ovarian Neoplasms and Peritoneal Neoplasms, sponsored by Novartis Pharmaceuticals.
NCT00035100 is a Phase 2 study of Ovarian Neoplasms and Peritoneal Neoplasms that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 54 participants, below the 366-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (85% lower). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035100, a Phase 2 study of Ovarian Neoplasms and Peritoneal Neoplasms, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the United States is complete but the study is still enrolling in other countries.
Primary Outcome
tumor response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
Conditions Studied
Interventions
- DRUG epothilone b
Study Locations (8)
Other
- Novartis Investigative Site - Amsterdam
- Novartis Investigative Site - Zwolle
- Novartis Investigative Site - Bratislava
- Novartis Investigative Site - Košice
- Novartis Investigative Site - Surrey
New Jersey
- Novartis Investigative Site - New Brunswick
Ontario
- Novartis Investigative Site - Toronto
Netherlands
- Novartis Investigative Site - Enschede
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2001-09 |
| Phase | Phase 2 |
What the finished NCT00035100 record still lists
NCT00035100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 366-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Ovarian Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which epothilone b is the first listed.
NCT00035100 lists 8 locations in 4 states (Other, New Jersey, Ontario).
Frequently Asked Questions
What is clinical trial NCT00035100 about?
NCT00035100 is a clinical study titled "EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer". This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the United States is complete but t...
What is the current status of trial NCT00035100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2001-09.
What conditions does trial NCT00035100 study?
This clinical trial studies the following conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms.
What interventions are being tested in trial NCT00035100?
The interventions under investigation include: epothilone b (DRUG).
Who is sponsoring clinical trial NCT00035100?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00035100 being conducted?
This trial has 8 study locations across New Jersey, Ontario, Netherlands. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00035100's enrollment target sits among peer trials
54 31st of 38 higher than 8 of 38 other Ovarian Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Vigil for Participants With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
COMPLETED · Phase 2
-
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia